Gene:
GCK
glucokinase (hexokinase 4)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  HK4
PharmGKB Accession Id: PA28610

Details

Cytogenetic Location: chr7 : p15.3 - p15.1
GP mRNA Boundary: chr7 : 44183870 - 44229022
GP Gene Boundary: chr7 : 44180870 - 44239022
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics
    Representation of anti-diabetic drugs repaglinide, nateglinide and sulfonylurea effects on insulin secretion in pancreatic cells.

External Pathways

Links to non-PharmGKB pathways.

  1. FOXA2 and FOXA3 transcription factor networks - (Pathway Interaction Database NCI-Nature Curated)
  2. HIF-1-alpha transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
  3. Negative Regulation of Glucokinase by Glucokinase Regulatory Protein - (Reactome via Pathway Interaction Database)

Publications related to GCK: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American journal of human genetics. 2012. Asselbergs Folkert W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature genetics. 2012. Manning Alisa K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of genetic variants previously associated with fasting glucose and insulin in the diabetes prevention program. PloS one. 2012. Florez Jose C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature genetics. 2010. Dupuis Josée, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug discovery today. 2009. Pal Manojit. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. Journal of cellular physiology. 2002. Zhou Jie, et al. PubMed

LinkOuts

UniProtKB:
HXK4_HUMAN (P35557)
Q53Y25_HUMAN (Q53Y25)
Ensembl:
ENSG00000106633
GenAtlas:
GCK
GeneCard:
GCK
MutDB:
GCK
ALFRED:
LO093690B
HuGE:
GCK
Comparative Toxicogenomics Database:
2645
ModBase:
P35557
HumanCyc Gene:
HS02935
HGNC:
4195

Common Searches